Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-25-00166)

Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Matrai, Z.; Sanna, A.; Qiu, L.; Feng, R.; Hua, V. M.; Jurczak, W.; Ritgen, M.; Yi, S.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.

doi:10.1200/JCO-25-01700

The article by Sharman et al entitled "Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/ Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor- Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)" (Journal of Clinical Oncology 10.1200/JCO-25-00166) was published online June 06, 2025, with errors. Figure A2, Forest plot of TTNT, was duplicated for Figure A1, Forest plot of IRC-assessed PFS. This has been corrected as of July 29, 2025. We apologize for the errors.

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-25-00166) / Sharman, J.P., Munir, T., Grosicki, S., Roeker, L.E., Burke, J.M., Chen, C.I., Grzasko, N., Follows, G., Matrai, Z., Sanna, A., Qiu, L., Feng, R., Hua, V.M., Jurczak, W., Ritgen, M., Yi, S., Bosch, F., Coombs, C.C., Bao, K., Patel, V., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - (2025). [10.1200/JCO-25-01700]